At the intersection of brain chemistry and body weight lies a gene most people have never heard of. NEGR1¹¹ NEGR1
Neuronal Growth Regulator 1 — a GPI-anchored cell adhesion molecule belonging to the IgLON superfamily. It is expressed on the neuronal surface and regulates the physical contacts between developing neurons encodes a molecular "social glue" that neurons use to recognize and bond with each other. Variants in NEGR1 have been replicated across virtually every major depression genome-wide association study (GWAS) of the past decade, making it one of the most robust genetic risk genes for mood disorders identified to date. What makes NEGR1 unusual is that it also shows up in obesity GWAS — hinting that the same hypothalamic wiring that shapes emotional resilience also governs feeding behavior and energy balance.

The Mechanism

NEGR1 belongs to the IgLON family²² IgLON family
A family of immunoglobulin-domain cell adhesion molecules (CAMs) including LSAMP, OPCML, NRCAM, NEGR1, and NTROPHY that regulate neuronal connectivity during development and in the adult brain. Each family member has three immunoglobulin domains and a GPI anchor attaching it to the outer leaflet of the cell membrane — proteins that physically hold neurons together and guide the growth of axons and dendrites. NEGR1 controls three critical aspects of neural architecture: neuronal outgrowth³³ neuronal outgrowth
The extension of axons and dendrites as neurons establish their long-range connections during development and maintain structural plasticity in adulthood, dendritic arborization, and synaptogenesis⁴⁴ synaptogenesis
The formation of synapses — the junctions where two neurons communicate. Reduced synaptogenesis leads to fewer and weaker connections, which is a hallmark of depression at the cellular level.

In the hippocampus — the brain region most responsible for emotional memory, stress regulation, and adult neurogenesis — NEGR1 deficiency has striking consequences. In Noh et al. 2019⁵⁵ Noh et al. 2019
Noh K et al. Negr1 controls adult hippocampal neurogenesis and affective behaviors. Molecular Psychiatry, 2019, mice without NEGR1 showed severely impaired long-term potentiation⁶⁶ long-term potentiation
LTP — the cellular basis of learning and memory, where repeated stimulation strengthens synaptic connections. LTP impairment in the dentate gyrus is strongly associated with depression-like states in animal models (LTP) in the dentate gyrus, sharply reduced adult neurogenesis, and depression/anxiety-like behaviors in validated behavioral assays. The mechanistic pathway involves the interaction of NEGR1 with the LIFR-Lcn2 axis⁷⁷ LIFR-Lcn2 axis
NEGR1 binds to leukemia inhibitory factor receptor (LIFR), which triggers production of Lipocalin-2 (Lcn2). Lcn2 is essential for hippocampal neurogenesis and mood regulation — restoring Lcn2 expression in NEGR1-knockout mice reverses the behavioral and neurogenic deficits: NEGR1 activates the LIFR receptor, which drives Lcn2 expression, which in turn is required for normal hippocampal cell growth.

Beyond the hippocampus, NEGR1 is expressed in hypothalamic circuits regulating both mood and feeding behavior. A 2022 study by Kaare et al.⁸⁸ Kaare et al.
Kaare M et al. Depression-Associated Negr1 Gene-Deficiency Induces Alterations in the Monoaminergic Neurotransmission Enhancing Time-Dependent Sensitization to Amphetamine in Male Mice. Brain Sciences, 2022 demonstrated that NEGR1-deficient mice show altered signaling across all three monoamine systems: elevated striatal dopamine release, higher hippocampal serotonin levels, and dysregulated norepinephrine responses. Significantly, escitalopram treatment rescued reduced hippocampal volume in these animals — suggesting the SSRI's therapeutic effect partly operates through the NEGR1-related neurogenic pathway.

The Evidence

The NEGR1 locus first reached genome-wide significance for depression in the landmark Hyde et al. 2016⁹⁹ Hyde et al. 2016
Hyde CL et al. Identification of 15 genetic loci associated with risk of major depression in individuals of European descent. Nature Genetics, 2016 study using 23andMe data (N=307,354), which identified rs11209948 as the lead NEGR1 SNP. This finding was independently confirmed in the Levey et al. 2021¹⁰¹⁰ Levey et al. 2021
Levey DF et al. Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions. Nature Neuroscience, 2021 mega-analysis (N=1,154,267), which identified the NEGR1 lead variant rs7531118 at p=8.9×10⁻²⁹ and characterized it as a brain eQTL¹¹¹¹ brain eQTL
A genetic variant that acts as an expression quantitative trait locus — meaning it statistically predicts the expression level of NEGR1 in brain tissue. The Levey study found this effect specifically in the hypothalamus, linking the GWAS signal to reduced NEGR1 expression in a depression-relevant brain region for NEGR1 expression in the hypothalamus.

Integrative analysis by Wang et al. 2020¹²¹² Wang et al. 2020
Wang X et al. Integrating genome-wide association study and expression quantitative trait loci data identifies NEGR1 as a causal risk gene of major depression disorder. Journal of Affective Disorders, 2020 linked the GWAS signal to causal NEGR1 expression changes: rs10789336 significantly affected NEGR1 expression in prefrontal cortex (P=5.14×10⁻³) and correlated with methylation at three CpG sites. The same variant was also associated with general cognitive function (P=2.65×10⁻¹²) and educational attainment (P=1.75×10⁻¹⁴), underscoring NEGR1's role in broad neurocognitive function.

The depression-obesity connection was formally quantified by Zhang et al. 2024¹³¹³ Zhang et al. 2024
Zhang H et al. Dissecting shared genetic architecture between depression and body mass index. BMC Medicine, 2024: genetic correlation between MDD and BMI is rg=0.19 (P=4×10⁻²⁶), and NEGR1 emerged as the top shared gene at genome-wide significance. Expression of NEGR1 was significantly lower in brain tissues of individuals with both depression and obesity, concentrated in the nucleus accumbens and anterior cingulate cortex.

Practical Implications

For G-allele carriers, the key leverage points are the NEGR1 gene's two main functions: hippocampal neurogenesis and hypothalamic monoamine organization. Adult hippocampal neurogenesis is one of the few brain processes that responds robustly to behavioral intervention — BDNF (brain-derived neurotrophic factor), the master regulator of neurogenesis, is strongly upregulated by aerobic exercise and certain dietary compounds. Given that the NEGR1-Lcn2 pathway is itself pro-neurogenic, G-allele carriers have a biologically motivated reason to prioritize neurogenesis-supporting interventions. The monoaminergic dysregulation observed in NEGR1-deficient animals also explains the clinical observation that SSRI treatment appears effective in carriers — escitalopram rescued hippocampal volume in animal models through pathways overlapping the NEGR1 circuit.

The dual mood-metabolic nature of NEGR1 means that interventions that simultaneously support neurogenesis and metabolic health (such as dietary protein adequacy and omega-3 intake) may be particularly relevant for G-allele carriers compared to the general population.

Interactions

NEGR1 variants interact with BDNF (rs6265): since NEGR1 drives hippocampal neurogenesis through the LIFR-Lcn2 axis, and BDNF is the master neurogenic signal, carriers of both risk alleles (NEGR1 G and BDNF Met/Met) face compounded impairment of hippocampal neuroplasticity. This combination would benefit most from consistent aerobic exercise, the most reliably effective way to upregulate BDNF and hippocampal neurogenesis simultaneously.

COMT (rs4680) represents a relevant monoaminergic interaction: the Kaare et al. 2022 data showing dysregulated dopamine and norepinephrine in NEGR1-deficient animals suggests that slow COMT (Met/Met) individuals who also carry the NEGR1 G allele may have compounded monoamine signaling abnormalities, particularly under stress. This combination warrants attention to stress-triggered mood episodes.

Interleukin-12 (IL-12)¹¹ Interleukin-12 (IL-12)
A heterodimeric cytokine secreted by dendritic cells and macrophages after pathogen sensing; it drives naive CD4+ T cells toward the Th1 phenotype, activates NK cells, and sustains IFN-γ production — the core of cellular immunity against intracellular pathogens is one of the master switches of adaptive immunity. Its receptor on T and NK cells consists of two subunits: IL-12Rβ1 (encoded by IL12RB1) and IL-12Rβ2 (encoded by IL12RB2). The β2 subunit is the key signaling component — it carries the intracellular domains that activate the JAK2/TYK2-STAT4 cascade, ultimately driving IFN-γ production and Th1 commitment. rs3790565 is an intronic variant within IL12RB2 on chromosome 1p31.3, approximately 11 kilobases from the better-studied rs3790567, which has reached genome-wide significance in primary biliary cholangitis (PBC) GWAS.

The Mechanism

rs3790565 lies within intron sequence of IL12RB2 but is located in a region with regulatory potential. The C allele (the minor allele globally, at ~24% frequency) is the variant of interest. While the intronic position means it does not alter the IL-12Rβ2 protein sequence, intronic variants at this locus are known to influence IL12RB2 expression levels, potentially affecting the density of functional IL-12 receptors on T cell and NK cell surfaces.

IL-12Rβ2 expression is the critical gating step for IL-12 responsiveness²² IL-12Rβ2 expression is the critical gating step for IL-12 responsiveness
Szabo et al. 2000 established that Th1/Th2 polarization is regulated in vivo by differential expression of the β2 subunit — cells without β2 cannot respond to IL-12 regardless of cytokine levels. When β2 expression is altered — whether by intronic regulatory variants, epigenetic modification, or cytokine feedback — the magnitude of IL-12 signaling in responding T cells shifts. This directly adjusts the balance between Th1-dominated responses (targeted at intracellular pathogens, also driving many autoimmune processes) and Th2/Th17 responses (atopic disease, allergy). Variants in this locus are therefore positioned at a central immune decision point with downstream consequences for both protective immunity and autoimmune risk.

The Evidence

The strongest evidence linking IL12RB2 genetic variation to disease comes from genome-wide association studies of primary biliary cholangitis (PBC), an autoimmune liver disease with a hallmark Th1 inflammatory signature. Hirschfield et al. 2009³³ Hirschfield et al. 2009
536 PBC cases and 1,536 controls; first GWAS to identify non-HLA PBC risk loci including IL12RB2; rs3790567 at the same locus reached p=2.76×10⁻¹¹, OR=1.51 established IL12RB2 as a bona fide PBC susceptibility gene. A follow-up Immunochip study⁴⁴ Immunochip study
Juran et al. 2012 — 2,426 PBC patients and 5,731 controls confirmed the locus, refined the association signal, and notably identified an epistatic interaction between the IL12RB2 risk locus at 1p31 and the IRF5 locus at 7q32 — suggesting that these two regulatory genes amplify each other's effect on PBC susceptibility.

rs3790565 itself has been directly genotyped in a Chinese Han allergic rhinitis study⁵⁵ Chinese Han allergic rhinitis study
Wei et al. 2015 — 543 cases and 749 controls; rs3790565 among three IL-12Rβ2 SNPs genotyped by PCR-RFLP and in a study of IL-12/IL-27 receptor variants and endometriosis organ involvement⁶⁶ IL-12/IL-27 receptor variants and endometriosis organ involvement
Zare et al. 2023 — Iranian patients. Both conditions involve Th1/Th2 imbalance: allergic rhinitis reflects Th2-skewed airway immunity, while endometriosis shows aberrant Th1 signaling contributing to peritoneal inflammation.

The broader IL23R-IL12RB2 intergenic region has been independently implicated in Behçet's disease — Fei et al. 2010 GWAS⁷⁷ Fei et al. 2010 GWAS
2,430 Behçet's cases, 2,660 controls; rs924080 in the IL23R-IL12RB2 region reached p=6.69×10⁻⁹, OR=1.28 — consistent with the role of this chromosomal neighborhood in multiple Th1-predominant inflammatory conditions.

The evidence level for rs3790565 specifically is moderate: the SNP sits in a locus with strong mechanistic and GWAS support, but the specific variant has not yet reached genome-wide significance in any single study. Its association signals in allergic rhinitis and endometriosis are suggestive but not yet definitively replicated at scale.

Practical Implications

C allele carriers (CC or CT at rs3790565) carry the minor allele at a locus where the disease-associated haplotype has been linked to IL-12 pathway dysregulation and Th1 autoimmune conditions. The most clinically meaningful associations at the IL12RB2 locus center on conditions with strong Th1 immune signatures: primary biliary cholangitis, Behçet's disease, and potentially other autoimmune liver and mucosal conditions. No supplement or dietary intervention has been shown to specifically modify IL-12Rβ2 expression in carriers of intronic variants. The actionable response is surveillance — knowing which conditions carry elevated risk and recognizing early symptoms.

Interactions

rs3790565 is in the same IL12RB2 locus as rs3790567⁸⁸ rs3790567
The neighboring IL12RB2 SNP approximately 11kb away that reached p=2.76×10⁻¹¹ for PBC in the Hirschfield GWAS; carriers of rs3790567 risk allele show elevated anti-mitochondrial antibody titers in PBC (PMID 28299343) and rs6679356 — both of which have been more extensively studied in PBC natural history. The IL12RB2 risk locus at 1p31 shows documented epistasis with IRF5⁹⁹ IRF5
Interferon regulatory factor 5, a key transcription factor downstream of innate immune sensing; its interaction with IL12RB2 identified in Immunochip PBC analysis (PMID 22936693) at 7q32, suggesting that combined risk at both loci amplifies autoimmune liver disease susceptibility.

rs2104286 (IL2RA) is a related T-cell regulation SNP that overlaps in the autoimmune spectrum and may combine with IL12RB2 variants through convergent effects on T-cell activation thresholds.

Not all genetic variants that matter change an amino acid. Toll-Like Receptor 2 (TLR2)¹¹ Toll-Like Receptor 2 (TLR2)
the frontline innate immune receptor that detects bacterial lipoproteins, peptidoglycan, and mycobacterial components on the surface of macrophages and dendritic cells carries a synonymous variant — rs3804099, also written as T597C or 19216T/C — where a single nucleotide change in the coding sequence leaves the encoded amino acid identical but may not leave TLR2 function unchanged. In silico analysis predicts a 70% probability that the C allele creates or disrupts a splice site, potentially altering TLR2 mRNA processing and steady-state transcript levels. The variant has been studied across tuberculosis cohorts, cancer registries, inflammatory bowel disease treatment trials, and bacterial infection datasets, painting a picture of a functionally relevant variant whose effect is population-specific and context-dependent.

The rs3804099 C allele is the minor allele in most populations, with frequencies ranging from roughly 12% in Africans to 40% in East Asians, making it far more common globally than the R753Q variant (rs5743708) in the same gene, which is almost exclusively European. This means most users encountering TLR2 findings will have rs3804099 results rather than R753Q results.

The Mechanism

Unlike the R753Q missense variant (rs5743708)²² R753Q missense variant (rs5743708)
which directly disrupts TLR2's TIR domain structure, reducing signaling by 42-fold, rs3804099 does not change the TLR2 protein sequence. Instead, it operates at the RNA level. The nucleotide substitution (c.597T>C in some annotations, placed in exon 3 of TLR2) is predicted to alter splicing regulatory elements³³ splicing regulatory elements
exonic splicing enhancers and silencers that guide spliceosome assembly. An in silico analysis found a 70% probability that this substitution affects mRNA splicing, a mechanism increasingly recognized as a route through which synonymous variants influence gene function. A 2022 study in smokers and COPD patients found that individuals with CC homozygosity had significantly less FEV1 decline and that CT heterozygotes showed reduced neutrophil and macrophage numbers over time compared with TT individuals, consistent with altered TLR2 expression or isoform usage. A 2024 study examining TLR-2 expression in response to SARS-CoV-2 spike protein found that C allele carriers (CT and CC genotypes) could not mount the same downregulation of TLR-2 positive non-switched B cells as TT individuals, indicating that the C allele changes how TLR2 responds to viral challenge at the cellular level.

The Evidence

The clearest signal comes from cancer susceptibility, where rs3804099 consistently shows a modest protective effect of the C allele. A meta-analysis of 47 case-control studies comprising 15,851 cancer cases and 21,182 controls⁴⁴ 47 case-control studies comprising 15,851 cancer cases and 21,182 controls
spanning gastric, hepatocellular, colorectal, and other cancers found that carriers of the C allele (CT or CC genotypes) had significantly lower cancer risk compared with TT homozygotes, with overall OR of 0.85 (95% CI 0.74–0.97, p=0.016) in the dominant model. The effect was strongest in Asians (OR 0.69 for CT vs TT, 95% CI 0.55–0.87), consistent with the higher baseline C allele frequency in East Asian populations. For hepatocellular carcinoma specifically, the heterozygous CT genotype was associated with significantly decreased HCC risk compared to TT, in a study of 300 HCC cases and 360 controls. The biological interpretation is that the C allele may increase TLR2-mediated innate immune surveillance of malignant or pre-malignant cells, though the exact mechanism remains under investigation.

For tuberculosis, the picture is more complex. An individual case-control study in 341 Han Chinese TB patients and 386 controls⁵⁵ 341 Han Chinese TB patients and 386 controls
including 230 pulmonary TB and 111 tuberculous meningitis patients found that the CC genotype was associated with increased pulmonary TB susceptibility in a recessive model (OR 2.22, 95% CI 1.18–4.17), with the association specific to pulmonary rather than meningeal TB and more pronounced in males. A Western Chinese cohort found significant associations specifically in retreatment TB (patients who relapsed or failed initial therapy) rather than primary TB. A Han Taiwanese study identified a C-T haplotype across rs3804099 and the adjacent rs3804100 that conferred increased TB risk. However, meta-analyses tell a more cautious story: an earlier Asian-focused meta-analysis of 8 studies (2,175 TB cases, 2,069 controls) found no significant association across genetic models for the T597C variant (OR 0.95, 95% CI 0.86–1.04). A broader meta-analysis found modest significance in the overall pooled population. This discrepancy reflects heterogeneity across populations, TB types, and analytic models — the CC genotype may represent a genuine risk factor in specific ethnic or epidemiological contexts rather than a universal effect.

In inflammatory bowel disease, rs3804099 emerged from a systematic review as a predictor of anti-TNF drug response. A Danish study of 738 IBD patients treated with infliximab or adalimumab⁶⁶ Danish study of 738 IBD patients treated with infliximab or adalimumab
including 256 UC patients and 482 CD patients found that patients carrying the CT or CC genotype had more than twice the odds of responding to anti-TNF therapy compared with TT homozygotes (OR 2.17, 95% CI 1.35–3.47). The authors proposed that genetically determined reduced IL-1β and IL-6 production (associated with the C allele) may create a lower baseline inflammatory tone that responds more favorably to TNF blockade. This is a pharmacogenomic finding, not a disease susceptibility finding — having the C allele does not predispose to IBD, but if you develop IBD and require biologic therapy, it may predict your response.

Practical Implications

The clinical picture from rs3804099 is genuinely nuanced. The CC genotype occupies an unusual position: it appears to be a risk factor for pulmonary tuberculosis (in certain Asian populations and specifically in retreatment TB contexts), yet simultaneously confers modest protection against several cancers and better response to anti-TNF therapy in IBD. This paradox may reflect the immunological trade-off at the heart of TLR2 biology — a TLR2 that responds more vigorously (TT) is better at initial mycobacterial clearance but may also drive more cancer-promoting chronic inflammation; a TLR2 with altered expression or splicing (CC) may mount a blunted initial anti-mycobacterial response while reducing chronic inflammatory cancer risk.

For the TT genotype, which is the common form, the evidence suggests somewhat more robust initial TLR2-mediated innate immune responses, but without the cancer-protective attenuation of chronic signaling.

Interactions

rs3804099 is studied together with rs3804100⁷⁷ rs3804100
a closely adjacent synonymous TLR2 variant in exon 3 in strong linkage disequilibrium with rs3804099 in Asian populations in haplotype analyses — the C-T haplotype (rs3804099 C + rs3804100 T) appears to be the TB-risk haplotype in Han Taiwanese, suggesting the two variants act together or that rs3804099 tags a broader functional haplotype block.

For individuals who also carry TLR2 R753Q (rs5743708), the innate immune system faces both a structural signaling defect (R753Q) and a potential expression-level alteration (rs3804099) at the same gene, though these two variants are on different haplotype blocks and both appear to reach significance independently in TB studies. Their combined effect has not been formally studied.

STAT3¹¹ STAT3
Signal Transducer and Activator of Transcription 3 — a transcription factor that converts cytokine receptor signals (IL-6, IL-10, IL-21, IL-23, and many others) into gene expression changes occupies one of the most contested positions in immunology: it is simultaneously required for anti-inflammatory resolution and for driving the Th17 cell differentiation that underlies autoimmune pathology. This intronic variant at position 42,346,255 on chromosome 17 sits inside STAT3 and has been independently associated with autoimmune thyroid disease, inflammatory bowel disease, psoriasis, and lung cancer across populations spanning New Zealand, Poland, and Turkey. Unusually, the T allele — the majority allele, carried by roughly two thirds of the global population — is the risk variant, while the minority C allele is protective.

The Mechanism

rs3816769 is an intronic variant that does not alter the STAT3 protein sequence directly. The preliminary gene expression data from Domańska et al. (2013) suggest the TT genotype correlates with higher STAT3 transcript levels in non-small cell lung cancer tissue (p=0.0464), which fits the broader biology: elevated STAT3 expression is a double-edged sword. Acute, transient STAT3 activation resolves inflammation by driving IL-10-producing regulatory cells and suppressing NF-κB. But chronic, constitutive STAT3 signaling — the kind that elevated baseline expression could produce — promotes Th17 differentiation, amplifies IL-17 and IL-21 production, sustains autoantibody-promoting follicular helper T cell programs, and drives tumour immune evasion. The rs3816769 intronic position may overlap an enhancer or splicing regulatory element²² enhancer or splicing regulatory element
Intronic regulatory sequences that control transcript isoform ratios or expression magnitude in immune cells that modulates how strongly STAT3 responds to cytokine stimulation. The variant is in strong linkage disequilibrium with rs744166 (another STAT3 intronic variant) and rs1053004, suggesting these SNPs travel together as a haplotype block and may collectively determine STAT3 regulatory output.

The Evidence

The most statistically robust finding comes from Ferguson et al.³³ Ferguson et al.
"Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population," Mutation Research 2010, a case-control study of 302 Crohn's disease patients and 382 controls. The C allele was significantly less frequent in CD patients than in controls (OR=0.71, 95% CI 0.56–0.89, p=0.003), confirming the C allele is protective. Notably, T-allele carriers showed significantly enhanced susceptibility to DNA damage in peripheral blood leukocytes (comet assay), a finding suggesting the variant affects not just immune signalling but genomic stability under inflammatory stress. T-allele carriers also had higher rates of colonic disease location and extra-intestinal manifestations.

In autoimmune thyroid disease, Kotkowska et al.⁴⁴ Kotkowska et al.
"Single nucleotide polymorphisms in the STAT3 gene influence AITD susceptibility, thyroid autoantibody levels, and IL6 and IL17 secretion," Cell Mol Biol Lett 2015 studied 71 AITD patients (39 Hashimoto's thyroiditis, 32 Graves' disease) and 40 controls, finding the C allele and CC genotype significantly over-represented in healthy controls. The CT genotype in Hashimoto's patients was associated with elevated thyroglobulin antibody (TgAb) titres — a direct measure of thyroid autoimmunity severity. The authors also observed that STAT3 genotype influenced ex vivo IL-6 and IL-17 secretion from peripheral blood cells, providing mechanistic support for the epidemiological associations.

In inflammatory bowel disease, Can et al.⁵⁵ Can et al.
"Investigation of IL23R, JAK2, and STAT3 gene polymorphisms in Crohn's disease and ulcerative colitis in a Turkish population," Turkish Journal of Gastroenterology 2016 found rs3816769 associated with Crohn's disease subphenotype and with requirement for immunosuppression in ulcerative colitis — suggesting the variant predicts disease severity beyond initial susceptibility.

A preliminary lung cancer study⁶⁶ preliminary lung cancer study
Domańska et al. 2013, 71 NSCLC patients vs 104 controls — treat as hypothesis-generating until replicated reported TT genotype association with both elevated NSCLC risk and higher tumour STAT3 expression. STAT3 is a well-validated oncogene and the expression correlation (p=0.0464) is biologically plausible, though the small sample warrants independent replication.

Practical Actions

For carriers of one or two T alleles, the actionable insight is about immune surveillance and inflammation monitoring rather than any single drug. Chronically elevated STAT3 signalling promotes Th17-mediated autoimmunity, so the priority is keeping the upstream cytokine environment that activates STAT3 — particularly IL-6, IL-17, and IL-23 — from running unchecked. Long-chain omega-3 fatty acids (EPA+DHA) suppress IL-6 and IL-17 production; adequate vitamin D maintains the T-regulatory/Th17 balance that STAT3 signalling mediates. For TT carriers with established autoimmune thyroid disease or IBD, JAK inhibitors (which block STAT3 phosphorylation) represent mechanistically matched systemic therapy options when standard first-line therapies are insufficient.

Interactions

rs3816769 is in strong LD with rs744166⁷⁷ rs744166
STAT3 intronic variant — associated with IBD, atopic dermatitis, and multiple autoimmune phenotypes across large GWAS studies and rs1053004⁸⁸ rs1053004
STAT3 intronic variant, part of the same haplotype block (r²=0.704 with rs3816769), and is co-listed in research with rs17881320⁹⁹ rs17881320
STAT3 intronic variant associated with atopic dermatitis (OR=1.09 in meta-analysis of 862,032 individuals). Together these STAT3 intronic variants likely form a regulatory haplotype that collectively sets STAT3 expression level and cytokine responsiveness in immune cells. The combined haplotype burden across the STAT3 locus may predict autoimmune risk more powerfully than any single variant.

Buried in the structure of every elastic tissue in your body — blood vessels, lungs, skin, eyes — is a protein called LOXL1 (Lysyl Oxidase-Like 1)¹¹ LOXL1 (Lysyl Oxidase-Like 1)
an enzyme that catalyzes the crosslinking of tropoelastin monomers into mature elastin fibers, giving connective tissues their resilience and recoil. Without functional LOXL1, elastin fibers fail to assemble properly, accumulating as disorganized fibrillar material in tissues throughout the body. The rs3825942 variant — changing glycine to aspartate at position 153 of the LOXL1 protein — is one of the most powerful single-gene risk factors for any common eye disease ever identified: exfoliation syndrome (XFS)²² exfoliation syndrome (XFS)
a systemic disorder characterized by the abnormal production and accumulation of fibrillar extracellular matrix material in ocular and systemic tissues, and the secondary glaucoma it causes.

The Mechanism

LOXL1 is essential for the periocular elastin scaffold. In the trabecular meshwork and lens zonules — the structures governing aqueous humor drainage and lens support in the eye — LOXL1 crosslinks elastin to maintain normal tissue architecture. The Gly153Asp substitution alters the propeptide domain³³ propeptide domain
the N-terminal proregion of LOXL1 that is cleaved during secretion; it regulates enzyme targeting and extracellular matrix deposition, disrupting LOXL1's ability to correctly position elastin crosslinks. The result is progressive accumulation of exfoliation material⁴⁴ progressive accumulation of exfoliation material
a fibrillar aggregate of abnormally crosslinked elastin, fibrillin-1, and other matrix proteins that clogs the trabecular meshwork and impairs aqueous drainage, raising intraocular pressure and damaging the optic nerve.

The connection to cardiovascular health is not incidental. Exfoliation syndrome is now recognized as a systemic elastosis⁵⁵ systemic elastosis
a body-wide disorder of elastic fiber metabolism, not merely an eye disease: exfoliation deposits have been identified in the heart, lungs, liver, kidneys, abdominal aorta, and cerebral arteries. Patients with exfoliation syndrome show [elevated plasma homocysteine | a marker of endothelial dysfunction and oxidative stress, and an independent cardiovascular risk factor], impaired conduit artery compliance, parasympathetic cardiovascular neuropathy, and increased rates of myocardial dysfunction and aortic aneurysm⁶⁶ aortic aneurysm
abnormal widening of the aorta due to weakened elastic wall structure.

The Evidence

The landmark discovery came in 2007 when Thorleifsson et al. published in Science⁷⁷ Thorleifsson et al. published in Science
Common sequence variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. Science 2007;317(5843):1397-1400 that rs3825942 and rs1048661 together explain almost all population-level susceptibility to exfoliation glaucoma. Individuals homozygous for the high-risk haplotype (GG at rs3825942) face over 100-fold elevated risk⁸⁸ over 100-fold elevated risk
a population-attributable risk exceeding 99% in Icelandic cohorts — one of the highest effect sizes ever reported for a common genetic variant.

Replication was rapid and global. Hewitt et al. 2008⁹⁹ Hewitt et al. 2008
Ancestral LOXL1 variants associated with pseudoexfoliation in Caucasian Australians. Human Mol Genet 2008;17(5):710-6 confirmed that Caucasian Australians share the same GG risk haplotype with OR 7.20 (95% CI 3.04–20.75) versus non-carriers, though with 9-fold lower disease penetrance than Nordic populations — suggesting environmental or epistatic modifiers drive clinical expression. Yamamoto et al. 2008¹⁰¹⁰ Yamamoto et al. 2008
Confirmed the GG genotype significantly associated with exfoliation glaucoma in Japanese patients (p=2.1×10⁻⁸) under a recessive model, though the rs1048661 variant shows a population-dependent risk allele reversal between European (G allele risk) and East Asian (T allele risk) populations.

An updated meta-analysis of 5,022 cases and 8,962 controls¹¹¹¹ updated meta-analysis of 5,022 cases and 8,962 controls
Li et al. 2021, PLoS One PMID 33909695 confirmed rs3825942 as a significant XFS/XFG risk factor across Caucasian, Asian, and African populations, though with pronounced variation in effect size by ancestry. The 2016 meta-analysis of 25 studies¹²¹² 2016 meta-analysis of 25 studies
Wang et al. J Glaucoma PMID 25304275 found that in Black South African populations, the AA genotype confers risk — a full reversal of the European allele-risk direction — underscoring that this variant's clinical interpretation must account for ancestry.

Practical Actions

For people of European ancestry with GG genotype, this represents a major risk factor for exfoliation glaucoma — the most common identifiable cause of secondary glaucoma worldwide. Since glaucoma is typically asymptomatic until significant optic nerve damage has occurred, proactive monitoring is the critical intervention. Annual dilated eye exams with intraocular pressure measurement¹³¹³ Annual dilated eye exams with intraocular pressure measurement
IOP elevation is the primary modifiable risk factor in glaucoma; early detection enables treatment before vision loss can identify exfoliation deposits, zonular laxity, and early optic nerve changes before functional vision loss.

Because XFS is a systemic condition, the cardiovascular implications warrant attention alongside the ophthalmologic ones. Holló 2018¹⁴¹⁴ Holló 2018
Vascular Dysfunction in Exfoliation Syndrome, J Glaucoma documents conduit artery stiffness, parasympathetic dysfunction, and elevated homocysteine as systemic vascular features of the syndrome — risk factors that may benefit from targeted management.

Interactions

The rs3825942 G153D variant does not act alone. The adjacent rs1048661 variant (R141L, Arg141Leu) in the same exon of LOXL1 acts in concert with rs3825942 — the two variants form a haplotype, and carrying GG at both positions identifies the highest-risk individuals. A third variant, rs2165241 (intronic), also contributes to XFS risk in Europeans but not significantly in Asians. Together, these three variants tag the LOXL1 risk haplotype that accounts for nearly all population-attributable risk for exfoliation glaucoma in Europeans.

The systemic elastin connection also creates a potential interaction with genes governing fibrillin-1 (FBN1) and other extracellular matrix proteins — LOXL1 deposits co-localize with fibrillin-1 in exfoliation material, and both are essential for elastic fiber microfibril assembly. Variants in FBN1 (Marfan syndrome pathway) and related matrix genes may compound the connective tissue vulnerability conferred by rs3825942.

Obscurin — encoded by OBSCN on chromosome 1q42 — is one of the largest proteins in the human body, a giant sarcomeric scaffold of nearly 800 kDa expressed in both cardiac and skeletal muscle. At the M-band and Z-disks of each sarcomere, obscurin tethers the sarcoplasmic reticulum to the myofibrils¹¹ obscurin tethers the sarcoplasmic reticulum to the myofibrils
Obscurin coordinates myofibrillogenesis, SR anchorage, and calcium homeostasis during contraction. Protein-truncating variants in OBSCN create a premature stop codon early in the transcript, eliminating the protein's C-terminal kinase and RhoGEF domains and stripping the SR of its structural anchor. When both copies of OBSCN carry such a truncation — homozygous or compound heterozygous — the resulting obscurin deficiency leaves skeletal muscle fibers highly vulnerable to injury from exertion or fever.

The Mechanism

This protein-truncating frameshift (c.708del, p.Ala237fs) removes a cytosine from an early coding exon, creating a frameshift that triggers nonsense-mediated decay of the transcript and eliminates full-length obscurin protein from muscle. Patient muscle biopsies from individuals with bi-allelic OBSCN loss show greatly reduced obscurin isoforms by Western blot²² Patient muscle biopsies from individuals with bi-allelic OBSCN loss show greatly reduced obscurin isoforms by Western blot
Reduction confirmed in 2 of 6 patients in Cabrera-Serrano 2022; consistent with NMD of the truncated transcript. Without obscurin, the sarcoplasmic reticulum loses its structural coupling to the sarcomere. In cultured myoblasts from affected individuals, the SR pumps calcium back more slowly under metabolic stress, suggesting impaired SERCA2a function or SR membrane integrity. This predisposes muscle fibers to cytotoxic calcium overload and membrane rupture — the cellular events underlying rhabdomyolysis. The disease follows a strict autosomal recessive pattern: heterozygous carriers in population databases and published cohorts do not show rhabdomyolysis, and monoallelic OBSCN truncation is not sufficient to produce this phenotype.

The Evidence

The pivotal study by Cabrera-Serrano et al. 2022³³ Cabrera-Serrano et al. 2022
Brain, 145(11):3985–3998, n=6 unrelated patients identified 10 bi-allelic loss-of-function OBSCN variants in 6 patients presenting with recurrent severe rhabdomyolysis. Onset was in the teenage years (ages 12–27 at first episode). Triggers included exercise (4 patients), heat (2 patients), prolonged travel (1 patient), and spontaneous episodes. Creatine kinase values during episodes reached 10,000–80,000 U/L, far above the clinical threshold for rhabdomyolysis (>5× ULN, ~1,000 U/L). None of the six patients had cardiomyopathy on echocardiography, distinguishing this biallelic skeletal muscle phenotype from the monoallelic HCM risk described in other OBSCN studies.

A subsequent case series by Zemorshidi et al. 2024⁴⁴ Zemorshidi et al. 2024
Neuromuscular Disorders, 34(1):42–47 described two additional patients with novel OBSCN protein-truncating variants presenting with muscle cramps, exercise intolerance, myoglobinuria, and rhabdomyolysis without cardiac involvement, expanding the genotypic breadth of the condition.

The specific frameshift variant captured by this locus (c.708del, ClinVar VCV003772679) is classified pathogenic by a neuromuscular genetics center, with an allele frequency of approximately 0.0001 (1 in 10,000) in gnomAD — consistent with the expected carrier frequency for a rare autosomal recessive disorder. No homozygotes appear in gnomAD, as expected for a severe pediatric/adolescent-onset condition.

Practical Implications

The key clinical action for bi-allelic carriers is trigger avoidance combined with an emergency response protocol for suspected episodes. Rhabdomyolysis in OBSCN-deficient individuals tends to be severe; CK values in published cases commonly exceed 30,000 U/L and can reach 80,000 U/L or higher, risking acute kidney injury. Intravenous fluid resuscitation (urine alkalinization, aggressive hydration) is the cornerstone of acute management and should be initiated early. Genetic counseling for affected individuals and their first-degree relatives is important: parents are obligate heterozygous carriers with no elevated rhabdomyolysis risk themselves.

Interactions

The monoallelic cardiac risk of OBSCN truncating variants — association with HCM in heterozygous carriers (rs71180793 and the OBSCN truncating variant class, OR 3.58 in Wu et al. 2021) — is a distinct phenotype from the biallelic skeletal rhabdomyolysis described here. Heterozygous carriers of this specific frameshift have no documented rhabdomyolysis risk based on current evidence.

Every time your body breaks down a protein that used biotin as a cofactor, it produces biocytin — a biotin molecule still attached to a lysine residue. Recovering that biotin for reuse is the job of biotinidase¹¹ biotinidase
the enzyme encoded by the BTD gene on chromosome 3p25.1; it cleaves the amide bond between biotin and lysine in biocytin, releasing free biotin for re-loading onto the next carboxylase enzyme. When biotinidase activity falls too low, biotin cannot be recycled, and the four biotin-dependent carboxylases — pyruvate carboxylase, propionyl-CoA carboxylase, 3-methylcrotonyl-CoA carboxylase, and acetyl-CoA carboxylase — begin to fail, disrupting fatty acid synthesis, gluconeogenesis, and amino acid catabolism simultaneously.

The rs397507172 variant substitutes glycine for valine at position 89 of the biotinidase protein (p.Val89Gly, c.266T>G). It is extremely rare — essentially absent in population databases — and was observed in a newborn screening cohort²² newborn screening cohort
Mühl A et al. Molecular characterisation of 34 patients with biotinidase deficiency ascertained by newborn screening and family investigation. Eur J Hum Genet, 2001 investigating the spectrum of BTD mutations in Austria.

The Mechanism

The BTD protein is a 523-amino-acid serine hydrolase containing three catalytic residues: His92 (proton acceptor), Asp192 (proton donor), and Ser225 (nucleophile). Val89 sits only three positions upstream of the catalytic His92. The substitution of a bulky, hydrophobic valine with the tiny, conformationally flexible glycine at position 89 is expected to destabilize the local α-helix and alter the positioning of the active-site histidine.

In vitro activity studies³³ In vitro activity studies
Borsatto T et al. Effect of BTD gene variants on in vitro biotinidase activity. Mol Genet Metab, 2019 across a range of BTD missense variants demonstrated that mutations close to the catalytic triad consistently produce severe reductions in enzyme activity — the p.Leu40Pro variant (also near the N-terminal region) showed 33% intracellular and only 7% extracellular activity, while p.Cys160Tyr produced 14% and 0.3%, respectively. No direct in vitro measurement is available for Val89Gly, but its proximity to His92 makes functional disruption biologically plausible. This variant has not been entered into ClinVar as of April 2026; it is formally classified as a variant of uncertain significance pending enzyme activity confirmation.

The Evidence

Biotinidase deficiency follows autosomal recessive inheritance. The clinical framework rests on enzyme activity thresholds established by Wolf and colleagues⁴⁴ Wolf and colleagues
Wolf B. Biotinidase Deficiency. GeneReviews, 2026. Updated February 19, 2026: profound deficiency is defined as <10% of mean normal serum biotinidase activity, partial deficiency as 10–30%. Heterozygous carriers (one functional allele, one variant allele) typically show ~50% of normal activity and are asymptomatic; they do not require biotin therapy and are not at risk for the disorder.

The clinical significance of rs397507172 for heterozygous carriers is therefore limited to reproductive counseling: if both partners carry a pathogenic BTD allele, each pregnancy faces a 25% chance of biallelic inheritance and clinical deficiency. A large reproductive carrier screening study⁵⁵ reproductive carrier screening study
Benn P et al. Evaluating reproductive carrier screening using biotinidase deficiency as a model. Genet Med, 2025 of 91,637 women found 6.1% carry at least one P/LP BTD variant, underscoring the importance of partner testing when a BTD variant is identified.

Practical Actions

For heterozygous carriers, the primary action is genetic counseling and partner testing. No biotin supplementation is required under normal conditions. If a partner is also found to carry a pathogenic BTD variant, preconception or prenatal testing options should be discussed.

For the extremely rare case of homozygous or compound heterozygous inheritance, the treatment is pharmacological biotin supplementation: 5–10 mg/day oral free biotin for profound deficiency, 2.5–10 mg/day for partial deficiency. Because neonatal biotin stores are depleted within the first few weeks of life without recycling, enzyme activity testing and treatment should begin in the newborn period. All children born in countries with universal newborn screening will be identified if they have significant biotinidase deficiency; genetic testing of parents and siblings after a proband is found adds important reproductive risk information.

Interactions

BTD is an autosomal recessive gene, so compound heterozygosity matters: a carrier of rs397507172 (one G allele) who also carries a second pathogenic BTD variant on the other chromosome — particularly a severe allele causing profound deficiency — could produce offspring with partial or profound biotinidase deficiency. The D444H allele (rs13078881, the most common partial-deficiency allele at ~3.9% population frequency per Swango et al.⁶⁶ Swango et al.) is the most likely partner allele in compound heterozygous scenarios.

The interleukin-2 receptor alpha chain (IL-2Rα, also called CD25) sits at a critical junction in immune regulation. When IL-2 binds to its receptor on T cells, it triggers proliferation of both effector T cells that drive immune responses and regulatory T cells (Tregs) that shut them down. The balance between these two arms determines whether your immune system attacks pathogens appropriately or turns on your own tissues. rs41295061 is a regulatory region variant¹¹ regulatory region variant
Located at chr10:6,072,697 GRCh38 in the IL2RA locus, affecting transcription factor binding rather than protein sequence in the IL2RA locus that influences this fundamental balance.

The Mechanism

A proteome-wide allele-specific binding screen²² proteome-wide allele-specific binding screen
Butter et al. PLoS Genetics 2012, PMID 23028375 found that the transcription factor LEF1 binds approximately 8 times more strongly to the minor A allele at rs41295061 than to the common C allele. LEF1 is a downstream effector of the Wnt signaling pathway that regulates T cell development and survival. This differential binding suggests the A and C alleles create functionally different regulatory environments for IL2RA transcription. Separately, a functional study³³ functional study
Qu et al. J Immunol 2009, PMID 19794070 showed that rs41295061 marks one major IL2RA susceptibility locus, while a nearby independent variant tagged by rs3118470 further reduces IL2RA expression through a distinct mechanism.

The net result of common C allele homozygosity is lower soluble IL-2RA levels in circulation. Fine-mapping of the IL2RA locus⁴⁴ Fine-mapping of the IL2RA locus
Lowe et al. Nature Genetics 2007, PMID 17676041 found that T1D-risk IL2RA genotypes produce significantly lower concentrations of circulating soluble IL-2RA (p=6.28×10⁻²⁸), a biomarker that reflects regulatory T cell activity. Reduced IL-2 signaling through the IL-2Rα high-affinity complex impairs Treg maintenance, tilting the immune balance toward autoimmunity.

The Evidence

The association of rs41295061 with type 1 diabetes is among the strongest non-HLA genetic signals for this disease. A meta-analysis of 10 independent studies⁵⁵ meta-analysis of 10 independent studies
Tang et al. J Cell Mol Med 2015, PMID 26249556 totaling 32,646 individuals identified rs41295061 as one of the three most associated IL2RA SNPs for T1D, alongside rs11594656 and rs2104286. The minor A allele showed a protective odds ratio of 0.67 (95% CI: 0.60–0.76), meaning the C allele homozygote is the T1D-risk genotype.

The same variant has opposing effects in Graves' disease (autoimmune hyperthyroidism). A study of 1,474 Graves' disease patients⁶⁶ study of 1,474 Graves' disease patients
Chistiakov et al. Scand J Immunol 2011, PMID 21815908 found that the A allele confers increased Graves' risk (OR 1.43, p=0.001), with A allele carriers showing elevated soluble IL-2RA levels in both patients and healthy controls. This allele-specific direction reversal across autoimmune diseases is biologically plausible: the same IL-2 signaling axis can drive pathogenic immune responses in different directions depending on which immune cell populations dominate in each disease.

Beyond T1D and Graves' disease, rs41295061 shows modest associations with juvenile idiopathic arthritis⁷⁷ juvenile idiopathic arthritis
Hinks et al. Arthritis Rheum 2009, PMID 19116909 (OR 0.80 for A allele, p=0.05) and ANCA-associated vasculitis⁸⁸ ANCA-associated vasculitis
Carr et al. BMC Med Genet 2009, PMID 19265545 (p=0.0122), though these associations are weaker than the T1D signal. The IL2RA locus appears to influence broad immune dysregulation rather than a single disease-specific pathway.

Practical Implications

The CC genotype (the most common globally, ~83% of Europeans by Hardy-Weinberg estimate) is the T1D risk genotype. However, it is important to emphasize that T1D is a polygenic, multifactorial disease — HLA genotype alone accounts for ~50% of genetic risk, and rs41295061 is a contributing factor, not a deterministic predictor. The vast majority of CC homozygotes will never develop T1D. Monitoring for early signs of autoimmune disease is the most actionable response to this genotype.

The heterozygous AC genotype confers intermediate T1D risk reduction, and the rare AA homozygote is associated with meaningfully lower T1D susceptibility but modestly elevated Graves' disease risk.

For individuals with a family history of T1D, Graves' disease, or other autoimmune conditions, knowing rs41295061 status adds context to a genetic risk picture that should also include HLA typing, PTPN22 rs2476601, and CTLA4 rs3087243. IL2RA variants like this one are particularly relevant for understanding the IL-2 pathway's role in immune homeostasis.

Interactions

rs41295061 operates in the same IL2RA locus as rs2104286, the other major IL2RA T1D variant already in this database. These two variants have partially overlapping but independent effects: rs2104286 is an intronic variant with its own effect on IL2RA expression, while rs41295061 operates through a distinct regulatory mechanism involving LEF1 binding. Conditional regression analyses show rs3118470, a separate variant near rs41295061, confers additional independent risk after accounting for rs41295061 (p=5×10⁻³).

The IL2RA locus interacts functionally with PTPN22 rs2476601 (the R620W T-cell activation variant) and CTLA4 rs3087243 (the immune checkpoint variant). Both of those variants impair T-cell negative regulation through different mechanisms: PTPN22 reduces TCR signaling threshold while CTLA4 reduces co-stimulatory braking. Combined, these three regulatory pathway variants likely compound autoimmune susceptibility, though their joint effect has not been formally quantified in a multi-SNP interaction model.

Ghrelin is the stomach's hunger signal — it rises before meals and drives appetite through the growth hormone secretagogue receptor (GHSR-1a)¹¹ growth hormone secretagogue receptor (GHSR-1a)
The only known peripherally derived orexigenic receptor in humans; signals through both homeostatic hypothalamic circuits and mesolimbic reward pathways. How much GHSR protein is available in the brain determines how strongly ghrelin can drive eating behavior. rs490683 sits in the GHSR gene promoter, roughly 9 kb upstream of the coding sequence, at a site where the transcription factor nuclear factor 1 (NF-1)²² nuclear factor 1 (NF-1)
NF-1 proteins are a family of transcriptional activators that bind to TTGGCN₅GCCAA consensus sequences; they regulate expression of numerous genes involved in tissue homeostasis and energy metabolism normally binds and activates transcription. The rs490683-G allele preserves this binding site (the NF-1 consensus motif GCCA is intact); the C allele converts it to CCCA, disrupting binding and reducing promoter activity.

The Mechanism

Gel-shift (electrophoretic mobility shift assay) experiments from Mager et al. 2008³³ Mager et al. 2008
Finnish Diabetes Prevention Study group; N=507 overweight adults with impaired glucose tolerance; 3-year lifestyle intervention demonstrated that nuclear proteins bind to the G-allele sequence with 745% higher affinity than to the C-allele sequence. Reporter assays in Matzko et al. 2012⁴⁴ Matzko et al. 2012
Bariatric surgery cohort at Geisinger Clinic; N>650 RYGB patients followed 30 months confirmed that the CC genotype (both alleles disrupting NF-1 binding) reduces GHSR promoter activity by approximately 20% compared to the GG genotype. The result is a measurable difference in ghrelin receptor density: GG individuals express more GHSR in appetite-regulating brain regions, making them more sensitive to circulating ghrelin and creating a stronger biological pull toward eating during energy restriction.

The Evidence

The Finnish Diabetes Prevention Study⁵⁵ Finnish Diabetes Prevention Study
507 overweight adults with impaired glucose tolerance randomized to intensive lifestyle intervention vs. control; 3-year follow-up; rs490683 was one of 7 GHSR variants genotyped found that rs490683-CC individuals showed the highest weight loss in the entire study population (p=0.032). The association extended to glucose metabolism: CC carriers maintained lower two-hour plasma glucose levels compared to CG heterozygotes (p=0.020) through the follow-up period. This functional SNP was the strongest GHSR variant in the study in terms of metabolic and weight outcomes.

Surgical validation came from a 650-patient RYGB cohort⁶⁶ 650-patient RYGB cohort
Roux-en-Y gastric bypass patients at Geisinger Health System; 30-month post-surgical follow-up; genotyped for 4 GHSR promoter variants where CC genotype again predicted the most weight loss post-operatively (additive model p=0.011, dominant model p<0.0097). The consistency across lifestyle intervention and bariatric surgery settings strengthens the causal interpretation.

The most recent and most direct test used a meal-replacement hypocaloric diet⁷⁷ meal-replacement hypocaloric diet
N=96 obese adults (BMI>35); normocaloric hyperproteic formula twice daily for 12 weeks; Spanish population: non-G-allele carriers (CC genotype) lost an average of 8.5 kg vs. only 2.6 kg in G-allele carriers (p=0.01), representing a 3.3-fold difference in weight loss response to the same dietary intervention. Fat mass loss (-7.7 vs -2.6 kg), waist circumference reduction (-7.2 vs -2.9 cm), fasting glucose change (-12.1 vs -3.1 mg/dL), and insulin reduction (-10.8 vs -3.9 IU/L) all followed the same pattern. G-allele carriers also consumed significantly more calories, carbohydrates, fats, and proteins during the dietary intervention period, consistent with elevated ghrelin receptor signaling overriding dietary restraint.

Practical Actions

For GG individuals (the majority of the population), higher baseline GHSR expression means that ghrelin signaling is stronger during caloric restriction — the biological pull toward eating is more powerful and more persistent than in CC carriers. This does not mean dietary interventions cannot work; it means they face a genuine biological headwind. Strategies that reduce ghrelin levels most effectively — high-protein meals, resistance training, adequate sleep — take on added importance. Monitoring weight response to dietary interventions and adjusting protocol when responses are modest helps GG individuals find what works rather than attributing poor results to personal failure.

For GC heterozygotes, one functional copy of the NF-1 site remains intact, producing an intermediate expression level and intermediate intervention response.

CC carriers represent the minority who derive the greatest benefit from dietary restriction programs and should expect above-average weight loss responses to structured interventions.

Interactions

rs490683 sits in the same GHSR promoter haplotype block as rs2922126 and rs9819506, which are also on the platform. Carriers of multiple GHSR promoter risk variants may experience compounding effects on ghrelin receptor expression beyond what any single variant predicts. The ghrelin ligand side of the system is covered by rs696217 (GHRL Leu72Met), which affects postprandial ghrelin suppression; individuals carrying both impaired ghrelin suppression (rs696217 T allele) and elevated ghrelin receptor expression (rs490683 GG) may face additive appetite dysregulation affecting both the ligand level and the receptor sensitivity simultaneously.

On the short arm of chromosome 9, an intronic variant in TTC39B¹¹ TTC39B
Tetratricopeptide Repeat Domain-Containing Protein 39B — a cytoplasmic scaffold protein that controls the degradation rate of liver X receptors has emerged as one of only a handful of robustly confirmed genetic risk factors for endometriosis. The rs519664 T allele increases endometriosis risk by approximately 29% and carries an even stronger association with severe, surgically confirmed stage III/IV disease. That a gene best known for regulating HDL cholesterol metabolism is linked to a gynaecological condition characterised by chronic peritoneal inflammation points to an underappreciated role of lipid-mediated immune signalling in the development and persistence of endometriotic lesions.

The Mechanism

TTC39B acts as an E3 ubiquitin ligase adaptor that targets liver X receptors (LXRα and LXRβ)²² liver X receptors (LXRα and LXRβ)
nuclear receptors activated by oxysterols — oxidised cholesterol derivatives — that control genes for reverse cholesterol transport, fatty acid synthesis, and inflammation for proteasomal degradation. When TTC39B is functional, LXR protein is continually degraded; when TTC39B activity is reduced, LXR accumulates and drives stronger expression of its target genes — including ABCA1 (intestinal HDL biogenesis) and a suite of anti-inflammatory and cholesterol-efflux genes.

How does this connect to endometriosis? LXR is a known anti-inflammatory transcription factor that suppresses NF-κB signalling and reduces prostaglandin production in macrophages and stromal cells. The peritoneal fluid of women with endometriosis is a highly pro-inflammatory environment rich in activated macrophages, elevated prostaglandin E2 (PGE2), and altered lipid mediator profiles. A TTC39B variant that modulates LXR protein stability would alter the balance between pro-inflammatory and pro-resolution lipid signalling in precisely those peritoneal macrophages that are thought to facilitate endometriotic lesion survival, vascularisation, and immune evasion. The intronic rs519664 variant does not itself change the TTC39B protein, but a nearby region has been identified as a putative regulatory element with physical interactions with the TTC39B promoter — suggesting the T allele alters TTC39B expression rather than function.

The Evidence

The endometriosis association was discovered by Steinthorsdottir et al. 2016³³ Steinthorsdottir et al. 2016
Common variants upstream of KDR encoding VEGFR2 and in TTC39B associate with endometriosis. Nat Commun. 2016 through a whole-genome-sequencing-based GWAS in Iceland (1,840 cases, 129,016 control women), with replication in a Danish cohort. The combined odds ratio for rs519664[T] was 1.29 (p=4.8×10⁻¹⁰). The association was stronger for histologically confirmed stage III/IV disease (OR 1.35, p=1.9×10⁻⁵) than for minimal/mild stage I/II disease (OR 1.21, p=0.013), suggesting the variant particularly predisposes to severe, deeply invasive endometriosis.

The TTC39B locus was subsequently replicated in the large-scale meta-analysis by Sapkota et al. 2017⁴⁴ Sapkota et al. 2017
Meta-analysis identifies five novel loci associated with endometriosis highlighting key genes involved in hormone metabolism. Nat Commun. 2017 (17,045 cases, 191,596 controls), which confirmed 19 independent endometriosis SNPs together explaining ~5% of disease variance. The biological mechanism underpinning the TTC39B locus was established by Tarling et al. 2016⁵⁵ Tarling et al. 2016
TTC39B deficiency stabilizes LXR reducing both atherosclerosis and steatohepatitis. Nature. 2016, which showed that TTC39B is an obligate co-factor for LXR ubiquitination: mice deficient in TTC39B had markedly elevated HDL-C and reduced atherosclerosis, all attributable to LXR protein stabilisation. The most recent large-scale endometriosis GWAS by Rahmioglu et al. 2023⁶⁶ Rahmioglu et al. 2023
The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions. Nat Genet. 2023 (60,674 cases, 701,926 controls) identified 42 genome-wide significant loci, including the 9p22 region, with effect sizes largest for stage 3/4 ovarian endometriosis.

The T allele is the minor allele in most populations: approximately 22% frequency in Europeans and South Asians, 14% in East Asians, and notably 75% in Africans — a marked frequency reversal that is important context for ancestry-specific risk counselling.

Practical Actions

The T allele raises endometriosis susceptibility at a population level — it is not deterministic. Among women who develop endometriosis, however, T carriers are more likely to progress to the severe stages that cause pelvic adhesions, ovarian endometriomas, and fertility impairment. Early gynaecological evaluation and prompt investigation of cyclical pelvic pain are therefore the most actionable implications of this genotype, since stage III/IV endometriosis diagnosed early can often be managed with less invasive intervention than disease allowed to progress for years.

The LXR-lipid connection also has a practical implication: peritoneal macrophage inflammatory tone and prostaglandin-driven pain are known targets of omega-3 fatty acid supplementation (EPA/DHA), which promotes pro-resolution lipid mediator production. While no endometriosis trial has stratified results by TTC39B genotype, omega-3 supplementation has a plausible mechanistic rationale for T carriers through the same LXR-mediated inflammatory pathway.

Interactions

rs519664 maps to a separate chromosomal region from the other robustly confirmed endometriosis loci, including rs17773813 (upstream of KDR/VEGFR2 on chromosome 4q12, discovered in the same Steinthorsdottir 2016 paper), rs2206949 (ESR1, the oestrogen receptor alpha locus), and multiple GWAS-identified loci involved in sex steroid hormone metabolism. No direct gene-gene interaction between TTC39B and other endometriosis loci has been studied in published datasets, but the combination of a TTC39B T allele (peritoneal inflammatory burden) with oestrogen-signalling loci (ESR1, FSHB) is biologically plausible given that oestrogen upregulates prostaglandin synthesis in endometriotic stroma — the same pathway TTC39B-LXR axis may modulate.